



## Caplacizumab

Revised: July 15, 2023.

CASRN: 915810-67-2

## Drug Levels and Effects

### Summary of Use during Lactation

No information is available on the clinical use of caplacizumab during breastfeeding. Because caplacizumab is a large protein molecule with a molecular weight of about 28,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Use of the drug after 2 weeks postpartum may minimize transfer to the infant.[1] Until more data become available, caplacizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Some opinion recommends that patients with acquired thrombotic thrombocytopenic purpura not breastfeed because anti-platelet sIgA might be present in milk and may adversely affect the infant.[2]

### Drug Levels

*Maternal Levels.* Relevant published information was not found as of the revision date.

*Infant Levels.* Relevant published information was not found as of the revision date.

### Effects in Breastfed Infants

Relevant published information was not found as of the revision date

### Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

### References

1. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. *Lancet Neurol.* 2023;22:350–66. PubMed PMID: 36931808.
2. Alijotas-Reig J. Acquired thrombotic thrombocytopenic purpura and pregnancy: More light than shade but controversies remain. *Thromb Res.* 2017;156:195–7. PubMed PMID: 28697902.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

**Attribution Statement:** LactMed is a registered trademark of the U.S. Department of Health and Human Services.

## Substance Identification

### Substance Name

Caplacizumab

### CAS Registry Number

915810-67-2

### Drug Class

Breast feeding

Lactation

Milk, Human

Antibodies, Monoclonal

Single-Domain Antibodies